# Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

> **NCT07271121** · PHASE2 · RECRUITING · sponsor: **King Hussein Cancer Center** · enrollment: 26 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma Refractory/ Relapsed

## Interventions

- **OTHER:** MB-CART-19.1

## Key facts

- **NCT ID:** NCT07271121
- **Lead sponsor:** King Hussein Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-12
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07271121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07271121, "Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07271121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*